Announcement Regarding CRS0540:

Crestone, Inc. and Praedicare Inc. Announce the Publication of Data on the Novel Antibiotic CRS0540 in the Hollow Fiber System Model of the Orphan Disease Disseminated Listeriosis

August 15, 2022—End-to-end drug development company Praedicare has found promise in a potential treatment for listeriosis using Crestone’s antibacterial drug candidate CRS0540. Read more about these exciting findings in the press release below, published on Cision PR Newswire’s website: